Accord Healthcare NL

Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 70 markets around the world.
 

DRUG REACTION REPORT

report

GROWTH’S IN OUR NATURE

With an extensive presence in all regions of the world, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies.

Our robust product portfolio in growth-oriented therapies allows us to compete with some of the biggest portfolios in the industry, as well as helps to extend our presence into new markets.

Accord’s operations were started with a strategic vision to create a global brand, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients around the world. We commit ourselves to challenging the unmet medical, societal and patient needs of the day.

01

TRULY INTERNATIONAL

Accord Healthcare is the international arm of Intas Pharmaceuticals Ltd., with commercial operations in more than 70 countries globally and over 35 European markets coverage. First Accord commercial operations in Europe were recorded in 2008 in the United Kingdom. Currently, our portfolio comprises 423 generic INNs, including 50 novel Added Value Products.

02

A COMPLETE APPROACH

Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.

03

European Focus

Accord currently holds over 9,300 Market Authorizations in Europe, with 4,000 SKU launches planned over the next 3 years. With presence in 35 European countries, Accord records 97% European patient’s coverage. Its portfolio includes the 1st EU approved biosimilar developed and licensed entirely by an Indian manufacturer.

Injexate ® (Methotrexate) Administration Guidelines Video.